Last reviewed · How we verify
Valsartan 160mg
Valsartan 160mg, marketed by Ohio State University, is an established drug in the cardiovascular segment. The key composition patent is set to expire in 2028, providing a clear period of exclusivity and potential revenue stability. The primary risk lies in the competitive landscape, where the entry of generics post-patent expiry could significantly erode market share.
At a glance
| Generic name | Valsartan 160mg |
|---|---|
| Also known as | Diovan, valsartan p.o. |
| Sponsor | Ohio State University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan (PHASE1, PHASE2)
- Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control (NA)
- Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation (PHASE4)
- Integration of Hypertension Management in HIV Care in Uganda (NA)
- Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition (PHASE3)
- To Evaluate the Safety and PK Characteristics in Healthy Volunteers-Livalozet (PHASE1)
- TRIGLYTZA® VERSUS METFORMIN IN OBESE ADULT TYPE 2 DIABETES (T2DM) PATIENTS OVER 24 WEEKS OF TREATMENT (PHASE2)
- The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |